Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Compounding Transparency topic
No spam. Unsubscribe anytime.
Sponsors ask committee to postpone bill targeting unapproved compounded weight‑loss drugs
Summary
Sponsors of a bill raising labeling and transparency requirements for compounded weight‑loss medications asked the Health & Human Services Committee to postpone the measure indefinitely while they continue stakeholder work. Sponsors cited safety concerns tied to non‑FDA‑approved products and misleading marketing.
Lawmakers on the House Health & Human Services Committee on Feb. 25 heard testimony from sponsors of a bill aimed at increasing transparency and patient protections for compounded weight‑loss medications, then agreed to postpone the measure indefinitely at the sponsors' request.
Representative Jackson, the bill's sponsor, said the proposal is a consumer‑protection measure intended to ensure patients understand when a compounded product is not FDA‑approved and to stop misleading marketing. "At its core, this bill is a consumer protection bill focused on transparency, labeling and ensuring that patients understand what they're receiving and the risks involved," she told the committee.
Co‑prime sponsor Representative Soper framed the issue around documented harms, citing university testing and clinical reports that, in his view, show safety failures in some compounded GLP‑1‑type products. Soper described a series of national news accounts and local reports of patients harmed after using unregulated or misrepresented products and urged continued attention to the issue even as sponsors asked for additional stakeholder work.
After witness time closed and sponsors returned to the table, Vice Chair Leiter moved — at the sponsors' request — that the committee postpone the bill indefinitely. Representative Frey seconded the motion and the chair announced the motion carried.
What happens next: The sponsors told the committee they intend to continue working with pharmacists, providers and other stakeholders to refine the bill and said they would reintroduce the measure when they believe implementation concerns are resolved.
